PASG

Analyst Note: Passage Bio, Inc. (PASG)

Date: 2026-06-13 Price: $6.18

1. Structural Readiness

• State: Context-only.
• Aggressive/Pre-Breakout Entry: — (Not actionable on its own; forming coils are partial readiness signals).
• Breakout Level: — (Not yet fired).
• Current Price: $6.18.
• Extension: — (No extension calculated as breakout has not fired).
• ATR Context: Current ATR is 21.9% (Extreme). This indicates severe volatility and high risk of whipsaw; sizing must be conservative relative to the structural setup.

2. Thesis Layer

This is a TACTICAL, setup-led name. As of 2026-06-13, there is no named macro or secular thesis attached to this ticker in the current context. The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the immediate business fundamentals (cash runway, restructuring progress, and clinical data delivery). Do not invent a thesis; the conviction must derive from the alignment of the structural setup with the company's specific operational milestones.

3. Business Overview

Passage Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, severe neurodegenerative diseases.

• Core Pipeline: The company's lead candidate, PBFT02, is designed to elevate progranulin levels to treat Frontotemporal Dementia (FTD) caused by *GRN* mutations. The company also maintains a portfolio including PBGM01 (for GM1 gangliosidosis), PBML04 (Metachromatic Leukodystrophy), PBAL05 (ALS), and PBCM06 (Charcot-Marie-Tooth Type 2A).
• Clinical Status: As of March 2026, the company was enrolling patients in Cohort 3 of its global trials. Management expected to report updated interim safety and biomarker data in the first half of 2026 and to declare a clinical candidate for a specific program in the second half of 2026.
• Financial Position & Restructuring: As of March 31, 2026, the company held $33.3 million in cash and cash equivalents. Management explicitly stated this amount was not sufficient to meet capital requirements over the next 12 months. Consequently, on April 20, 2026, the company initiated a review of strategic alternatives. On April 28, 2026, in connection with this review, the company announced a Restructuring Plan to reduce operating expenses by cutting the workforce by approximately 75%. The estimated aggregate severance and related costs for this plan are $3.3 million, to be recorded primarily in the second quarter of 2026.
• Partnerships: The company maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program and a development services agreement with Catalent Maryland, Inc.

4. Archetype and Conviction

• Archetype: Growth Leader (as per source layer), though currently in a Deep Value / Restructuring phase.
• *Fit:* The company fits the "Growth Leader" archetype historically due to its proprietary AAVhu68 capsid technology and pipeline for rare diseases. However, the current operational reality (75% workforce reduction, cash insufficiency, strategic review) aligns more closely with a Structurally Broken or Turnaround scenario where the business model is being radically compressed to extend runway.
• Valuation Context: The financial spine indicates forward consensus EPS of -9.212 for FY1 and -7.838 for FY2. The company is not yet profitable, and the negative earnings are expected to persist.
• Conviction Stack:
• *Thesis Strength:* Low (No named secular thesis; tactical only).
• *Evidence Quality:* Mixed. Strong on clinical data history (stabilization of MRI scores in GM1), but critical on cash runway (insufficient funds).
• *Structural Quality:* The forming coil suggests a potential bottoming process, but the 21.9% ATR (Extreme) is a significant negative signal for structural quality, indicating high volatility and potential for false breakouts.
• *Setup Readiness:* Partial. The coil is forming, but the breakout has not fired.
• *Rerating Potential:* Dependent on the successful execution of the strategic review (M&A, licensing, or financing) and the delivery of the expected H1 2026 clinical data.

5. Invalidations, Strengths, and Gaps

• Gaps in Evidence:
• Financing Outcome: There is no evidence yet on the *result* of the strategic alternatives review. The cash runway is insufficient for 12 months, creating an immediate existential risk if a deal is not struck.
• Clinical Data Specifics: While management *expected* to report data in H1 2026, the specific results of the Cohort 3 enrollment and the interim data release are not detailed in the provided evidence as of the report date.
• Post-Restructuring Runway: The evidence states the 75% cut will reduce expenses, but does not quantify the new cash runway or the specific timeline for the next capital raise.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key risks: Extreme ATR (21.9%) indicating high volatility and whipsaw risk; failure to secure strategic alternative financing before cash exhaustion; clinical data delays or negative results. Sizing hint: Minimal position size due to extreme volatility and binary nature of strategic review outcome. Expected path: Management executes restructuring to extend runway; strategic alternatives review concludes with a financing event or partnership; price stabilizes if clinical data meets expectations. Expected horizon: 3 to 6 months for strategic resolution and data delivery.